Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Brief Summary: The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.


Options:
A: Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169); Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population (Days 85, and 169 and postvisits on Days 28, 56, and 85)
B: Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks (16 weeks)
C: Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24 (Baseline to Week 24)
D: Change From Baseline in Synovial Tissue Messenger Ribonucleic Acid (mRNA) Expression at Day 28 (Day -7 (Baseline), Day 28); Change From Baseline in Protein Expression of Tumor Necrosis Factor Alpha (TNFalpha), Interleukin-6 (IL-6), Interleukin-17a (IL-17a) and Interleukin-10 (IL-10) at Day 28 (Baseline (Day -7), Day 28); Change From Baseline in Percentage of Area Stained For CD3+ and CD68+ Surface Markers of Inflammatory Cells of the Synovial Tissue at Day 28 (Baseline (Day -7), Day 28); Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Baseline (Day-7) (Baseline (Day -7)); Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Day 28 (Day 28); Blood Cytokine Level at Pre-dose on Day 1 (Pre-dose on Day 1); Blood Cytokine Level at 1 Hour Post-dose on Day 1 (1 hour post-dose on Day 1); Blood Cytokine Level at 4 Hours Post-dose on Day 1 (4 hours post-dose on Day 1); Blood Cytokine Level at Pre-dose on Day 10 (Pre-dose on Day 10); Blood Cytokine Level at Pre-dose on Day 28 (Pre-dose on Day 28); Blood Cytokine Level at 1 Hour Post-dose on Day 28 (1 Hour Post-dose on Day 28); Blood Cytokine Level at 4 Hours Post-dose on Day 28 (4 Hours Post-dose on Day 28); Blood Cytokine Level at 8 Hours Post-dose on Day 28 (8 Hours Post-dose on Day 28); Blood Cytokine Level at 24 Hours Post-dose on Day 28 (24 Hours Post-dose on Day 28); Blood Cytokine Level at Pre-dose on Day 35 or Early Termination (Pre-dose on Day 35 or Early Termination); Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 1 (Pre-dose on Day 1); Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 1 (1 Hour Post-dose on Day 1); Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 1 (4 Hours Post-dose on Day 1); Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 10 (Pre-dose on Day 10); Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 28 (Pre-dose on Day 28); Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 28 (1 Hour Post-dose on Day 28); Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 28 (4 Hours Post-dose on Day 28); Blood T, B and NK Lymphocyte Counts at 8 Hours Post-dose on Day 28 (8 Hours Post-dose on Day 28); Blood T, B and NK Lymphocyte Counts at 24 Hours Post-dose on Day 28 (24 Hours Post-dose on Day 28); Blood T, B and NK Lymphocyte Counts and Possible Subsets at Pre-dose on Day 35 or Early Termination (Pre-dose on Day 35 or Early Termination); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 1 (Pre-dose on Day 1); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 1 (1 Hour Post-dose on Day 1); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 1 (4 Hours Post-dose on Day 1); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 10 (Pre-dose on Day 10); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 28 (Pre-dose on Day 28); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 28 (1 Hour Post-dose on Day 28); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 28 (4 Hours Post-dose on Day 28); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 8 Hours Post-dose on Day 28 (8 Hours Post-dose on Day 28); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 24 Hours Post-dose on Day 28 (24 Hours Post-dose on Day 28); Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 35 or Early Termination (Pre-dose on Day 35 or Early Termination); Parathyroid Hormone (PTH) Level at Pre-dose on Day 1 (Pre-dose on Day 1); Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 1 (1 Hour Post-dose on Day 1); Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 1 (4 Hours Post-dose on Day 1); Parathyroid Hormone (PTH) Level at Pre-dose on Day 10 (Pre-dose on Day 10); Parathyroid Hormone (PTH) Level at Pre-dose on Day 28 (Pre-dose on Day 28); Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 28 (1 Hour Post-dose on Day 28); Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 28 (4 Hours Post-dose on Day 28); Parathyroid Hormone (PTH) Level at 8 Hours Post-dose on Day 28 (8 Hours Post-dose on Day 28); Parathyroid Hormone (PTH) Level at 24 Hours Post-dose on Day 28 (24 Hours Post-dose on Day 28); Parathyroid Hormone (PTH) Level at Pre-dose on Day 35 or Early Termination (Pre-dose on Day 35 or Early Termination); Osteoprotegerin (OPG) Level at Pre-dose on Day 1 (Pre-dose on Day 1); Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 1 (1 Hour Post-dose on Day 1); Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 1 (4 Hours Post-dose on Day 1); Osteoprotegerin (OPG) Level at Pre-dose on Day 10 (Pre-dose on Day 10); Osteoprotegerin (OPG) Level at Pre-dose on Day 28 (Pre-dose on Day 28); Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 28 (1 Hour Post-dose on Day 28); Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 28 (4 Hours Post-dose on Day 28); Osteoprotegerin (OPG) Level at 8 Hours Post-dose on Day 28 (8 Hours Post-dose on Day 28); Osteoprotegerin (OPG) Level at 24 Hours Post-dose on Day 28 (24 Hours Post-dose on Day 28); Osteoprotegerin(OPG) Level at Pre-dose on Day 35 or Early Termination (Pre-dose on Day 35 or Early Termination); Plasma Level of Matrix Metallopeptidase (MMP13) (Pre-dose on Day 1, 10, 28 and 35 or Early Termination; 1, 4 hours Post-dose on Day 1, 28; 8, 24 hours Post-dose on Day 28); Plasma Level of Interleukin-34 (IL-34) and Interleukin-18 (IL-18) (Pre-dose on Day 1, 10, 28 and 35 or Early Termination; 1, 4 hours Post-dose on Day 1, 28; 8, 24 hours Post-dose on Day 28); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 1 (Pre-dose on Day 1); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 1 (1 Hour Post-dose on Day 1); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 1 (4 Hours Post-dose on Day 1); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 10 (Pre-dose on Day 10); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 28 (Pre-dose on Day 28); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 28 (1 Hour Post-dose on Day 28); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 28 (4 Hours Post-dose on Day 28); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 8 Hours Post-dose on Day 28 (8 Hours Post-dose on Day 28); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 24 Hours Post-dose on Day 28 (24 Hours Post-dose on Day 28); Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 35 or Early Termination (Pre-dose on Day 35 or Early Termination); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 1 (Pre-dose on Day 1); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 1 (1 Hour Post-dose on Day 1); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 1 (4 Hours Post-dose on Day 1); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 10 (Pre-dose on Day 10); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 28 (Pre-dose on Day 28); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 28 (1 Hour Post-dose on Day 28); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 28 (4 Hours Post-dose on Day 28); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 8 Hours Post-dose on Day 28 (8 Hours Post-dose on Day 28); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 24 Hours Post-dose on Day 28 (24 Hours Post-dose on Day 28); Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 35 or Early Termination (Pre-dose on Day 35 or Early Termination); Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 1 (Pre-dose on Day 1); Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 10 (Pre-dose on Day 10); Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 28 (Pre-dose on Day 28); Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at 24 Hours Post-dose on Day 28 (24 Hours Post-dose on Day 28); Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 35 or Early Termination (Pre-dose on Day 35 or Early Termination)

Answer: A